Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Lv, Meng  [Clear All Filters]
2014
Lv M, Zhao X-S, Hu Y, Chang Y-J, Zhao X-Y, Kong Y, Zhang X-H, Xu L-P, Liu K-Y, Huang X-J. Monocytic and Promyelocytic Myeloid-derived suppressor cells may contribute to G-CSF-induced immune tolerance in haplo-identical allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014.
2015
Lv M, Huang X. Fighting against hematological malignancy in China: from unique system to global impact. Sci China Life Sci. 2015.
Zhang X-H, Wang G-X, Zhu H-H, Liu Y-R, Xu L-P, Han W, Chen H, Chen Y-H, Wang F-R, Wang J-Z, et al. Recruitment of CD8(+) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1(+) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2015.
2018
Huo M-R, Xu Y-J, Zhai S-Z, Lv M, Wang Y, Cao L-Q, Xu L-P, Zhang X-H, Chen H, Chen Y-H, et al. Prevalence and risk factors of antibodies to human leukocyte antigens in haploidentical stem cell transplantation candidates: A multi-center study. Hum Immunol. 2018.
Hu L-J, Zhao X-Y, Yu X-X, Lv M, Han T-T, Han W, Huang X-J. Quantity and Quality Reconstitution of NKG2A NK cells Are Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2018.
2020
Tang F-F, Sun Y-Q, Mo X-D, Lv M, Chen Y-H, Wang Y, Xu L-P, Zhang X-H, Huang X-J. The incidence, risk factors, and outcomes of primary prolonged isolated thrombocytopenia after haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2020.
Wang Y, Zhang J, Su Y, Wang C, Zhang G, Liu X, Chen Q, Lv M, Chang Y, Peng J, et al. miRNA-98-5p Targeting IGF2BP1 Induces Mesenchymal Stem Cell Apoptosis by Modulating PI3K/Akt and p53 in Immune Thrombocytopenia. Mol Ther Nucleic Acids. 2020;20:764-776.
2022
Li S-Q, Xu L, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Complement of an LSC-based MRD assay to the traditional MFC method for relapse prediction of AML: a prospective study. Blood. 2022.
Wang Y, Mo X, Cheng Y, Chen Y, Lv M, Wang F, Yan C, Han W, Chen H, Xu L, et al. Effects of CD34 cell dose on haematopoietic recovery in acute lymphoblastic leukaemia patients with positive pretransplant measurable residual disease. Int J Lab Hematol. 2022.
Luo X-Y, Kong Y, Lv M, Mo X-D, Wang Y, Xu L-P, Zhang X-H, Huang X-J, Tang F-F. The nuclear factor erythroid 2-related factor 2 agonist tert-butylhydroquinone improves bone marrow mesenchymal stromal cell function in prolonged isolated thrombocytopenia after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2022.
Sun X, Fu H, Wang C, Zhang Y, Han W, Chen H, Wang Y, Chen Q, He Y, Huang Q, et al. Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection. Bone Marrow Transplant. 2022.
2023
Kong J, Zheng F-M, Wang Z-D, Zhang Y-Y, Cheng Y-F, Fu H-X, Lv M, Chen H, Xu L-P, Zhang X-H, et al. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Huang Q-S, Han T-X, Chen Q, Wu J, Zhao P, Wu Y-J, He Y, Zhu X-L, Fu H-X, Wang F-R, et al. Clinical risk factors and prognostic model for patients with bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
Ma L, Xu L-P, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Effects of isolated central nervous system involvement evaluated by multiparameter flow cytometry prior to allografting on outcomes of patients with acute lymphoblastic leukemia. Front Oncol. 2023;13:1166990.
Shang Q-N, Yu X-X, Xu Z-L, Chen Y-H, Han T-T, Zhang Y-Y, Lv M, Sun Y-Q, Wang Y, Xu L-P, et al. Expanded clinical-grade NK cells exhibit stronger effects than primary NK cells against HCMV infection. Cell Mol Immunol. 2023.
Lv M, Guo H-D, Huang X-J. A perfect mismatch: haploidentical hematopoietic stem cell transplantation overtakes a bend. Cell Mol Immunol. 2023.
Huang Q-S, Han T-X, Fu H-X, Meng H, Zhao P, Wu Y-J, He Y, Zhu X-L, Wang F-R, Zhang Y-Y, et al. Prognostic factors and outcomes in patients with septic shock after allogeneic hematopoietic stem cell transplantation. Transplant Cell Ther. 2023.
Fu H, Lv M, Liu H, Sun Y, Zhang Y, Mo X, Han T, Wang F, Yan C, Wang Y, et al. Thrombopoietin level predicts the response to avatrombopag treatment for persistent thrombocytopenia after haploidentical haematopoietic stem cell transplantation. Bone Marrow Transplant. 2023.
2024
Fu H, Sun X, Lin R, Wang Y, Xuan L, Yao H, Zhang Y, Mo X, Lv M, Zheng F, et al. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial. BMC Med. 2024;22(1):85.
Ma R, Zhu D-P, Zhang X-H, Xu L-P, Wang Y, Mo X-D, Lv M, Zhang Y-Y, Cheng Y-F, Yan C-H, et al. Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience. Bone Marrow Transplant. 2024.